Skip to main content
. Author manuscript; available in PMC: 2013 Aug 12.
Published in final edited form as: Biomaterials. 2011 Mar 22;32(17):4118–4129. doi: 10.1016/j.biomaterials.2010.11.068

Fig. 1.

Fig. 1

A schematic drawing showing the composition of a drug-loaded G5-NAcGal conjugate binding to the ASGPR expressed on the surface of hepatic cancer cells (e.g. HepG2), which triggers receptor-mediated endocytosis of these G5-NAcGal conjugates followed by endosomal escape and release of the therapeutic cargo into the cytoplasm while the ASGPR recycles back to the cell surface.